ANDA 213328, held by Nivagen. Temozolomide.
As of Nov 16, 2026, ANDA 213328 (Temozolomide), held by Nivagen, was first approved by FDA on Nov 23, 2021, with 0 approved supplements and 0 published complete response letters.
Temozolomide capsules, USP is an alkylating drug indicated for the treatment of adult patients with:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 23, 2021 | Original application | Approved | None posted |
| Temozolomide5MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide20MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide100MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide140MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide180MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide250MG · capsule;oral | Temozolomide | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters